Changes in causes of death among persons with AIDS: San Francisco, California, 1996-2011

AIDS Patient Care and STDs

Volumn 28, Issue 10, 2014, Pages 517-523

  Schwarcz, Sandra K ^a,b   Vu, Annie ^a   Hsu, Ling Chin ^a   Hessol, Nancy A ^c  

^a SAN FRANCISCO DEPARTMENT OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANUS CANCER; ARTICLE; CARDIOMYOPATHY; CAUSE OF DEATH; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE REGISTRY; DISEASE SURVEILLANCE; DRUG OVERDOSE; FEMALE; GROUPS BY AGE; HIGH RISK BEHAVIOR; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIFE EXPECTANCY; LIVER CANCER; LIVER DISEASE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; PNEUMONIA; SEPTICEMIA; STANDARDIZED MORTALITY RATIO; SUBSTANCE ABUSE; SUICIDE; UNITED STATES; VIRUS HEPATITIS; ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; AIDS RELATED COMPLEX; COMPLICATION; EPIDEMIOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MIDDLE AGED; NEOPLASM; REGISTER; RISK FACTOR; SEXUAL BEHAVIOR; TRENDS; YOUNG ADULT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; CAUSE OF DEATH; HEPATITIS, VIRAL, HUMAN; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; RISK FACTORS; SAN FRANCISCO; SEXUAL BEHAVIOR; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84907693400     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2014.0079     Document Type: Article

References (51)

1. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006;43:27-34.
2. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann InternMed 2006; 145:397-406.
3. Lewden C, May, T, Rosenthal, E, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: The Mortalite 2000 and 2005 Surveys (ANRS EN19 and Mortavic). J Acquir Immune Defic Syndr 2008;48:590-598.
4. Fazito ELL, Vasconcelos NAM, Pereira MC. Causes of death among people living with HIV/AIDS in Brazil. Braz J Infect Dis 2010;14:558-553.
5. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200.
6. French AL, Gawel SH, Hershow R, et al. Trends in mortality and causes of death among women with HIV in the United States: A 10-year study. J Acquir Immune Defic Syndr 2009;51:399-406.
7. Lau B, Gange S, Moore RD. Risk of on-ART related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/ mm3. J Acquir Immune Defic Syndr 2007;44:179-187.
8. Simard EP, Pfeiffer RM, Engels EA. Mortality due to cancer among people with AIDS: A novel approach using registry-linkage data and population attributable risk methods. AIDS 2012;26:1311-1318.
9. The Antiretroviral Therapy Cohort Collaborative. Life expectancy of individual on combination antiretroviral therapy in high income countries: A collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299.
10. May M, Gompels M, Delpech, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ 2011;343 d6016.
11. Wada N, Jacobson LP, Cohen M, French A, Phair J, Munoz A. Cause-specific mortality among HIV-infected individuals, by CD4 + cell count at HAART initiation, compared with HIV-uninfected individuals. AIDS 2014;28:257-265.
12. Rodger AJ, Lodwick R, Schechter M, et al. Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS 2013;27:973-979.
13. The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group. Factors associated with specific causes of death amongst HIV-positive individuals in the D.A.D. Study. AIDS 2010;24:153148-153157.
14. The D.A.D Study Group. Liver-related deaths in persons infected with the human immunodeficiency virus. Arch Intern Med 2006;166:1632-1641.
15. Jarrett OD, Wanke CA, Ruthazer R, Bica I, Isaac R, Knox TA. Metabolic syndrome predicts all-cause mortality in persons with human immunodeficiency virus. AIDS Patient Care and STDs 2013;27:266-271.
16. Jain MK, Serenba E, Bhore R, et al. Change in fibrosis score as a predictor of mortality among HIV-infected patients with viral hepatitis. AIDS Patient Care STDs 2012;26:73-80.
17. The Antiretroviral Therapy Cohort Collaborative. Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with the general population in nine industrialized countries. Int J Epidemiol 2009;38:1624-1633.
18. Phillips AN, Neaton J, Lundgren JD. The role of HIV in serious diseases other than AIDS. AIDS 2008;22:2409-2418.
19. Page-Shafer K, Delorenze GN, Satariano WA, Winklestein W. Comorbidity and survival in HIV-infected men in the San Francisco Men's Health Survey. Ann Epidemiol 1996; 6:420-430.
20. Villanti A, German D, Sifkis F, Flynn C, Holtgrave D. smoking, HIV status, and HIV risk behaviors in a respondentdriven sample of injection drug users in Baltimore, Maryland: The BESURE study. AIDS Educ Prev 2012;24:132-147.
21. Galvan FH, Bing EG, Fleishman JA, et al. The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. J Stud Alcohol 2002;63:179-186.
22. Lifson AR, Lando HA. Smoking and HIV: Prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep 2012;9:223-230.
23. Scott HM, Vittinghoff E, Irvin R, et al. Age, race ethnicity and behavioral risk factors associated with per contact risk of HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2014;65:115-121.
24. The SMART/INSIGHT and the D.A.D. Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008;22:F17-F24.
25. Crane HM, Kestenbaum B, Harrington RD, Kitahata MM. Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir. AIDS 2007;21:1431-1439.
26. Goicoechea M, Liu S, Best B, et al. Greater tenofovirassociated renal function decline with protease inhibitor-based versus nonnucleoside reverse-Transcriptase inhibitor-based therapy. J Infect Dis 2008;197:102-108.
27. Islam FM, Wu Jianyun, Jasson J, Wilson DP. Relative risk of renal disease among people living with HIV: A systematic review and meta-Analysis. BMC Public Health 2012; 12:324 http://www.biomedcentral.com/1471-2458/12/234 (Last accessed April 4, 2014).
28. Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of cardiovascular disease among people living with HIV: A systematic review and meta-Analysis. HIV Med 2012;13:453-468.
29. Nunez M. Clinical syndromes and consequences of antiretroviral-related hepatotoxicity. Hepatology 2010;52: 1143-1155.
30. DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-1735.
31. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: A casecontrol study nested within the French Hospital Database ANRS Cohort CO4. Arch Intern Med 2010;170:1228-1238.
32. Armah KA, McGinnis K, Baker J, et al. HIV status, burden of comorbid disease and biomarkers of inflammation, altered coagulation and monocyte activation. Clin Infect Dis 2012;55:26-136.
33. Neuhaus J, Jacobs DR, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis 2010;201:1788-1795.
34. Effros RB, Fletcher CV, Gebo K, et al. Workshop on HIV infection and aging: What is known and future research directions. Clin Infect Dis 2008;47:542-553.
35. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PloS Medicine 2008;5:e203.
36. Centers for Disease Control and Prevention. HIV Surveillance Report, 2011; vol. 23. http://www.cdc.gov/hiv/topics/ surveillance/resources/reports/. Published February 2013 (Last accessed March 12, 2014).
37. San Francisco Department of Public Health. HIV/AIDS Epidemiology Annual Report, 2012. Available at: Www .sfdph.org/comupg/oprograms/hivepisec/default/asp (Last accessed August 30, 2013).
38. Chu PL, Hsu LC, Schwarcz SK. Comparison of methods to measure the completeness of HIV/AIDS reporting in San Francisco. In: Oral Abstract Session: XVII International AIDS Conference: Abstract no. THAC0106. Mexico City August 3-8, 2008.
39. World Health Organization. International Classification of Diseases and Related Health Problems. 9th Revison:1979. Available from: Ftp://ftp.cdc.gov/pub/Health-Statistics/NCHS/ Publications/ICD-9 (Last accessed January 25, 2012).
40. World Health Organization. International Classification of Diseases and Related Health Problems. 10th Revison:1999. Available from: Http://apps.who.int/classifications/icd10 (Last accessed January 25, 2012).
41. State of California, Department of Finance, Report P-3: State and County Population Projections by Race/Ethnicity, Detailed Age, and Gender, 2000-2050. Sacramento, California.
42. Dean AG, Sullivan KM, Soe MM. OpenEpi: Open Source Epidemiologic Statistics for Public Health, and according to tVersion.www.OpenEpi.com, updated 04/06/2013 (Last accessed December 20, 2013).
43. Rosner B. Fundamentals of Biostatistics, 5th ed., Duxbury, 2000, p. 606.
44. Mani D, Aboulafia DM. Screening guidelines for non-AIDS defining cancers in HIV-infected individuals. Curr Opin 2013;5:518-525.
45. Hoover KW, Butler M, Workowski KA, et al. Low rates of hepatitis screening and vaccination of HIV-infected MSM in HIV clinics. Sex Transm Dis 2012;39:349-353.
46. Jonckheere S, Vincent A, Belkhir L, Wilmes D, Vandercam B, Yombi JC. Adherence to screening guidelines for hepatitis C among HIV-positive patients. AIDS Patient Care STD 2013;27:317-319.
47. Office of the Chief Medical Examiner City and County of San Francisco Annual Report. 2005-2006, 63-65. Available at:http://sfgsa.org/index.aspx?page=943 (Last accessed February 22, 2013).
48. Office of the Chief Medical Examiner City and County of San Francisco Annual Report. 2006-2007, 130-133. Available at:http://sfgsa.org/index.aspx?page=943 (Last accessed February 22, 2013).
49. Office of the Chief Medical Examiner City and County of San Francisco Annual Report. 2007-2008, 135-138. Available at:http://sfgsa.org/index.aspx?page=943 (Last accessed February 22, 2013).
50. Office of the Chief Medical Examiner City and County of San Francisco Annual Report. 2008-2009, 142-145. Available at:http://sfgsa.org/index.aspx?page=943 (Last accessed February 22, 2013).
51. Office of the Chief Medical Examiner City and County of San Francisco Annual Report. 2009-2010, 144-148. Available at:http://sfgsa.org/index.aspx?page=943 (Last accessed February 22, 2013).